# Medpace Holdings, Inc.  Share Price Target ‘$415.20’, now 4.0% Upside Potential

- Link: https://www.directorstalkinterviews.com/medpace-holdings-inc.share-price-target-415.20-now-4.0-upside-potential/4121148627
- Published: 2024-03-22T13:52:11+00:00
- Author: Charlotte Edwards

**Medpace Holdings, Inc.** with ticker code (MEDP) now have 5 market analysts covering
the stock. The analyst consensus now points to a rating of ‘buy’. The target price
High/Low ranges between $480.00 and $340.00 calculating the average target share
price we see $415.20. (at the time of writing). Now with the previous closing price
of $399.05 and the analysts are correct then we can expect a percentage increase
in value of 4.0%. The day 50 moving average is $352.64 and the 200 day MA is $282.80.
The total market capitalization for the company now stands at 12.71B. The stock 
price for the company is currently $413.31 USD

 The potential market cap would be $13,227,640,318 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 46.49, revenue per share of $61.38
and a 13.99% return on assets.

Medpace Holdings, Inc. is a global provider of clinical research-based drug and 
medical device development services. The Company is focused on providing scientifically
driven outsourced clinical development services to the biotechnology, pharmaceutical
and medical device industries. The Company partners with pharmaceutical, biotechnology,
and medical device companies in the development and execution of clinical trials.
The Company’s drug development services focuses on full-service Phase I-IV clinical
development services and include development plan design, coordinated central laboratory,
project management, regulatory affairs, clinical monitoring, data management and
analysis, pharmacovigilance new drug application submissions, and post-marketing
clinical support. It also provides bio-analytical laboratory services, clinical 
human pharmacology, imaging services, and electrocardiography reading support for
clinical trials. Its operations are based in North America, Europe, and Asia.

Share on: